181
Participants
Start Date
November 30, 2010
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
IMGN901
Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
Carboplatin and Etoposide
Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
UPMC Cancer Centers East, Oxford Drive, Monroeville
UPMC Cancer Center St. Margaret, Pittsburgh
Univeristy of Pittsburg Medical Center, Pittsburgh
UPMC Cancer Center at UPMC Passavant (HOA), Pittsburgh
Sibley Memorial Hospital, Washington D.C.
Greater Baltimore Medical Center, Baltimore
Bayview Medical Center, Baltimore
Johns Hopkins University, Baltimore
Anne Arundel Medical Center, Annapolis
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario, Madrid
South Carolina Oncology Associates, Columbia
University of Florida, Gainesville
Holy Cross Hospital Bienes Comprehensive Cancer Center, Fort Lauderdale
Sarah Cannon Research Institute, Nashville
University of Tennessee Medical Center Cancer Institute, Knoxville
Hospital Universitario Virgen del Rocio, Seville
University Hospitals of Cleveland, Cleveland
Barbara Ann Karmanos Cancer Institute, Detroit
UTHSC at San Antonio, San Antonio
Arizona Cancer Center @ UMC North, Tucson
UCLA Oncology Center, Los Angeles
UCLA Oncology Clinic, Santa Monica
UCLA Hematology, Pasadena
UCLA Santa Clarita Valley Cancer Center, Valencia
UCLA Oncology Center, Westlake Village
St. Joseph's Hospital, Orange
Oregon Health and Science University, Portland
Northwest Medical Specialties, Tacoma
Yale Medical Center, New Haven
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Johnson Therurer Cancer Center at Hackensack, Hackensack
Oklahoma University, Oklahoma City
Juravinski Cancer Center, Hamilton
Montreal General Hospital, Montreal
Jewish General Hospital, Montreal
St. Mary's Hospital, Montreal
Royal Victoria, Montreal
Corporacio Sanitaria Parc Tauli, Sabadell
Hospital Vall d'Hebron, Barcelona
Hospital de la Santa Creu y Sand Pau, Barcelona
Royal Sussex Hospital, Brighton
University College of London, London
The Christie Hospital, Withington
Royal Marsden, Sutton
Royal Marsden, London, London
Lead Sponsor
ImmunoGen, Inc.
INDUSTRY